RedHill Biopharma Ltd.
RedHill Biopharma is a specialty biopharmaceutical company focused primarily on developing and commercializing drugs for gastrointestinal diseases, infectious diseases and oncology, with a primary focus on the U.S. Its principal executive offices are in Tel Aviv, Israel, and it has established the headquarters of its U.S. commercial operations in Raleigh, North Carolina. RedHill’s portfolio includes the FDA-approved Talicia, an oral combination capsule for treating H. pylori infection in adults, commercialized in the U.S. through Talicia Holdings under a joint commercialization agreement with Cumberland. The company also has five therapeutic candidates in development, including opaganib, RHB-104, RHB-204, RHB-102 (Bekinda) and RHB-107 (upamostat). It generates money from U.S. Talicia commercialization, with net revenues shared equally with Cumberland, and from licensing Talicia in certain territories outside the U.S. It licenses or collaborates with other companies to develop and commercialize products and candidates.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $RDHL in the last 7 days.
No SEC Form 4 filings for $RDHL in the last 30 days.
See all $RDHL insider activity →RedHill Biopharma announced that in vitro studies by leading microbiology centers confirmed RHB-204's ability to kill Mycobacterium avium subspecies paratuberculosis (MAP) and its comparability to RHB-104. RHB-104 previously showed 64% effectiveness in a Phase 3 trial for Crohn's disease. RHB-204 is a next-gen formulation designed for reduced toxicity and improved patient adherence.
RedHill Biopharma (RDHL) announced a $2.9M grant for trials of its drug opaganib combined with CAR T-cell therapy for multiple myeloma. The University of Oklahoma will conduct the trials, with RedHill providing opaganib. Preclinical studies suggest the combination may improve treatment outcomes. Opaganib targets the SPHK2 protein, potentially enhancing immune cell activity against cancer.
U.S. stocks declined midweek, with small caps hit hardest as 10-year Treasury yields rose to 5.24%. McCormick (MKC) reported Q3 sales up 17.4%, EPS $0.36. Conagra (CAG) saw Q1 sales down 1.4%, EPS up 5.1%. WTW (WTW) noted commercial property rate declines. RedHill (RDHL) outlined portfolio reset. Recon (RCON) reported 65.8% revenue growth, narrowed losses.
Recent RDHL coverage spans earnings, mergers & acquisitions and technology.
Positive pre‑clinical data may lift sentiment toward RedHill as it moves closer to a Phase 2 trial.
The grant supports early‑stage clinical work that could de‑risk the program and improve future valuation.
Positive as new product rights add growth potential.
Strategic acquisition and cash inflow improve liquidity and growth outlook.
The acquisition of Rebyota and Clenpiq adds two FDA‑approved GI products with $37.5M 2025 sales, likely boosting near‑term revenue and improving liquidity.
AlphAI scores every news story that mentions RDHL with an AI model for sentiment and relevance, and aggregates insider trades from RedHill Biopharma Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
RedHill Biopharma announced that in vitro studies by leading microbiology centers confirmed RHB-204's ability to kill Mycobacterium avium subspecies paratuberculosis (MAP) and its comparability to RHB-104. RHB-104 previously showed 64% effectiveness in a Phase 3 trial for Crohn's disease. RHB-204 is a next-gen formulation designed for reduced toxicity and improved patient adherence.
RedHill Biopharma (RDHL) announced a $2.9M grant for trials of its drug opaganib combined with CAR T-cell therapy for multiple myeloma. The University of Oklahoma will conduct the trials, with RedHill providing opaganib. Preclinical studies suggest the combination may improve treatment outcomes. Opaganib targets the SPHK2 protein, potentially enhancing immune cell activity against cancer.
U.S. stocks declined midweek, with small caps hit hardest as 10-year Treasury yields rose to 5.24%. McCormick (MKC) reported Q3 sales up 17.4%, EPS $0.36. Conagra (CAG) saw Q1 sales down 1.4%, EPS up 5.1%. WTW (WTW) noted commercial property rate declines. RedHill (RDHL) outlined portfolio reset. Recon (RCON) reported 65.8% revenue growth, narrowed losses.
U.S. stocks ended the week lower, with the Dow down 1.93%, S&P 500 down 1.25%, and Nasdaq down 0.90%. The Russell 2000 underperformed, falling 1.16%. The 10-year Treasury yield rose 6 basis points to 5.24%. Earnings reports from McCormick (MKC), Conagra (CAG), Recon Technology (RCON), Yiren Digital (YRD), and RedHill Biopharma (RDHL) were released.
RedHill Biopharma Ltd. (RDHL) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Press Release RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota ® and Clenpiq ® , two established FDA-approved gastrointe
RedHill Biopharma reported H1 2026 results, highlighting a strategic portfolio reset. The company acquired commercial rights to Rebyota® and Clenpiq® for $12M, funded by the $18M sale of Talicia®. These FDA-approved GI drugs generated $37.5M in 2025 net sales. RedHill aims to grow revenues and expand its pipeline, with ongoing R&D in oncology and GI indications. The company's CEO emphasized improved liquidity and growth potential. (350 characters)
RedHill Biopharma (RDHL) acquired global rights to Rebyota and U.S. rights to Clenpiq from Ferring for $12M upfront, with royalties of 5-20%. The products had $37.5M combined U.S. sales in 2025. Ferring retains manufacturing, while RedHill handles commercialization. Success depends on sales growth and supply reliability.
RedHill Biopharma (RDHL) acquired exclusive commercialization rights for Rebyota and Clenpiq from Ferring Pharmaceuticals, receiving $12M upfront. The deal expands RDHL's gastrointestinal drug portfolio. RDHL's P/S ratio is 0.64x, below its 10.8x historical median, indicating market skepticism. The company has a GF Score of 25/100, signaling financial and operational challenges, with a distress-level Altman Z-Score of -24.34.
RedHill Biopharma (RDHL) shares rose 64% after announcing the sale of its Talicia business to Apotex Health Corp. for $18M upfront and up to $35M in milestones. The stock traded at $1.08, up from a 52-week low of $0.57.
RedHill Biopharma (RDHL) sold its 70% stake in Talicia to Apotex (APTX) for $18M upfront and up to $35M in milestones. The deal strengthens RedHill's liquidity and funds its commercial expansion. Talicia treats H. pylori infections, a cause of gastric cancer and ulcers.
